Promising Results for Mavacamtem in Hypertrophic Obstructive Cardiomyopathy 
Results from the phase III EXPLORER- HCM trial, published in The Lancet, revealed that mavacamten, the selective allosteric inhibitor of cardiac myosin ATPase, is linked with enhancements in exercise capacity, left-ventricular outflow tract obstruction, New York Heart Association functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. Read more.

Empagliflozin Efficacious in Reduced Ejection Fraction HF 
According to results from a pivotal trial published in the New England Journal of Medicine, the use of the sodium–glucose cotransporter 2 inhibitor empagliflozin was linked with a lower combined risk for cardiovascular death or hospitalization for heart failure (HF) compared with placebo in patients receiving recommended therapy for heart failure, regardless of the presence of diabetes. Read more.

FDA Accepts NDA for Avacopan in ANCA-Associated Vasculitis
In a recent press release, the FDA announced the acceptance of the New Drug Application (NDA) for avacopan, which is a first-in-class, orally administered small molecule that employs a novel, highly targeted mode of action in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read more.